|
C3ORF58 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.29889999977983E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.06520000001609E-07 |
| Normal-vs-Stage2 |
4.25219999999893E-05 |
| Normal-vs-Stage3 |
1.0798000049661E-08 |
| Normal-vs-Stage4 |
8.14489997669199E-09 |
| Stage1-vs-Stage2 |
5.780600E-01 |
| Stage1-vs-Stage3 |
1.531940E-02 |
| Stage1-vs-Stage4 |
1.452180E-02 |
| Stage2-vs-Stage3 |
2.886400E-02 |
| Stage2-vs-Stage4 |
3.134400E-02 |
| Stage3-vs-Stage4 |
6.990800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.42869999958984E-08 |
| Normal-vs-AfricanAmerican |
6.43449999999657E-05 |
| Normal-vs-Asian |
2.22869999999542E-05 |
| Caucasian-vs-AfricanAmerican |
7.016800E-01 |
| Caucasian-vs-Asian |
1.565840E-01 |
| AfricanAmerican-vs-Asian |
5.455400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.90299999594623E-08 |
| Normal-vs-Female |
2.85299999958077E-07 |
| Male-vs-Female |
1.051560E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.12530000002154E-07 |
| Normal-vs-Age(41-60Yrs) |
7.36680000334999E-08 |
| Normal-vs-Age(61-80Yrs) |
4.91720000272977E-08 |
| Normal-vs-Age(81-100Yrs) |
1.256250E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.886200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.909200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.517600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.981800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.779200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.893200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.409200E-04 |
| Classical-VS-Follicular |
1.833430E-01 |
| Classical-VS-Other |
9.422600E-01 |
| Classical-VS-Normal |
3.66680000030151E-07 |
| Tall-VS-Follicular |
1.185080E-04 |
| Tall-VS-Other |
2.616800E-01 |
| Tall-VS-Normal |
6.43459951987779E-10 |
| Follicular-VS-Other |
7.296000E-01 |
| Follicular-VS-Normal |
2.19659999999289E-05 |
| Other-VS-Normal |
4.007800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.73429999992403E-07 |
| Normal-vs-N1 |
3.71899999684899E-09 |
| N0-vs-N1 |
6.356500E-03 |
|
|
